Innate immunity and genetic determinants of urinary tract infection susceptibility

Gabriela Godaly, Ines Ambite, and Catharina Svanborg

Purpose of review
Urinary tract infections (UTIs) are common, dangerous and interesting. Susceptible individuals experience multiple, often clustered episodes, and in a subset of patients, infections progress to acute pyelonephritis (APN), sometimes accompanied by uro-sepsis. Others develop asymptomatic bacteriuria (ABU). Here, we review the molecular basis for these differences, with the intention to distinguish exaggerated host responses that drive disease from attenuated responses that favour protection and to highlight the genetic basis for these extremes, based on knock-out mice and clinical studies.

Recent findings
The susceptibility to UTI is controlled by specific innate immune signalling and by promoter polymorphisms and transcription factors that modulate the expression of genes controlling these pathways. Gene deletions that disturb innate immune activation either favour asymptomatic bacteriuria or create acute morbidity and disease. Promoter polymorphisms and transcription factor variants affecting those genes are associated with susceptibility in UTI-prone patients.

Summary
It is time to start using genetics in UTI-prone patients, to improve diagnosis and to assess the risk for chronic sequels such as renal malfunction, hypertension, spontaneous abortions, dialysis and transplantation. Furthermore, the majority of UTI patients do not need follow-up, but for lack of molecular markers, they are unnecessarily investigated.

Keywords
genetics, innate immunity, urinary tract infection susceptibility

INTRODUCTION
The susceptibility to infection varies greatly, depending on the pathogen, exposure rate and individual. Genetic predisposition is essential, not just for rare monogenetic disorders but for common infections such as urinary tract infection (UTI), wherein disease-associated genetic variants primarily control the expression of genes involved in the antibacterial defense. Genetic determinants of UTI susceptibility work in concert with social and behavioural risk factors, structural or functional abnormalities, catheters, foreign bodies or surgery, all of which modify the penetrance of susceptibility genes. As the vast majority of UTI-prone patients lack such risk factors, genetic predisposition is a major determinant of UTI morbidity [1,2].

UTI susceptibility runs in families and UTI-prone individuals experience recurrent, often clustered infections with potentially severe complications, depending on the site of infection and type of UTI. In three-generation family pedigrees, an increased frequency of acute pyelonephritis (APN) was detected in both male and female family members of APN-prone children, compared with children without UTI [3]. There was no evidence of increased cystitis morbidity in those families, suggesting that different genetic mechanisms control APN and cystitis susceptibility. Several studies have associated personal and family histories of UTI with an increased risk of acute cystitis, and in one study, 42% of family members were cystitis-prone, compared with 11% of controls. The risk increased...
with the number of affected individuals, especially if a sister, mother or daughter had a history of UTI and the influence of behavioural factors was increased [4,5], consistent with a combined effect of genetics and exposure variables.

**INNATE IMMUNITY AND MOLECULAR MECHANISMS**

Most known UTI-associated genes control the innate immune response to infection [1]. Studies in mice carrying single gene deletions have demonstrated that the loss of specific innate immune functions creates strong phenotypes. Innate immune attenuation results in asymptomatic bacteriuria, while exaggerated, dysregulated responses drive disease (‘good’ versus ‘bad’ inflammation).

UTIs elicit a rapid innate immune response that has been extensively characterized [1,6,7]. The mucosa provides an efficient protective barrier against bacterial attack, but uropathogenic *Escherichia coli* (UPEC) are equipped to target the surface layer of epithelial cells, through specific adhesive interactions and then engage additional tissue compartments through a variety of toxic perturbations of the mucosa, sometimes followed by invasion [8]. Specific molecular recognition mechanisms determine the flavour of the innate immune response by activating different signalling pathways and effector functions [1,6,7]. For example, P-fimbriated *E. coli*, which account for 70–100% of febrile infections in patients with normal urinary tracts, are recognized by glycosphingolipid receptors [9]. Through the release of ceramide, Toll-like receptor 4 (TLR4) signalling is activated, through the TIR-domain-containing adapter-inducing interferon-β/TRIF-related adapter molecule (TRIF/TRAM) (where TIR is Toll/interleukin-1 receptor) adaptors, mitogen-activated protein kinases (MAPKs) and cAMP response element-binding protein 1 (CREB-1) phosphorylation and transcription factor activation [10,11]. The TRIF/TRAM or MyD88/TIR domain-containing adapter protein (TIRAP) adaptors that control the two main arms of TLR4 signalling [12] are differentially activated by UPEC, depending on their fimbrial expression profile. FimH may initiate TLR4 signalling through lipopolysaccharide (LPS), activating the MyD88 and TIRAP adaptors [12] and nuclear factor kappa B (NF-κB) transcription through MyD88 and TIRAP [13*]. Flagella activate TLR5 signalling [14] and numerous additional recognition and signalling mechanisms are being explored [15*,16*].

As a result of these interactions, infection activates an innate cascade, allowing antibacterial effector mechanisms to clear infection while maintaining tissue homeostasis [17**]. UPEC alter the expression of more than 1000 genes in human kidney cells, and in genetically competent mice, kidney or bladder infection modifies the expression of at least 500 genes, depending on the bacterial strain. These include well known responses such as chemokines and receptors for inflammatory cells, and cytokines [18,19], inflammasome and acute phase response genes, type I interferon (IFN), growth factors and antibacterial peptides [20*,21]. In addition, UTIs modify a large number of genes that have not yet been identified as determinants of resistance against infection, predicting that there are new categories of cellular and tissue responses to be explored.

**GENETIC CONTROL OF URINARY TRACT INFECTION IN THE MURINE MODEL**

Here, we discuss genetic control of innate immunity following the approximate order of activation by UPEC infection (Fig. 1). Gene deletions that prevent innate immune activation favour long-term bacteriuria without inflammation or disease. The early innate immune response to UTI is therefore low or absent in *Thr4* /− mice and in C3H/HeJ mice [22,23], carrying an inactivating mutation of the Toll/interleukin-1 receptor (TIR) homology domain of TLR4 [22,24–27]. As the antibacterial effector functions are suppressed, *Thr4* /− mice develop a state of asymptomatic bacteriuria (ABU) [28]. Infected *Trif* /− or *Myd88* /− mice develop a similar phenotype, with a low innate immune response and prolonged bacterial carriage [29]. Cytokine and neutrophil responses are virtually undetectable...
FIGURE 1. Genetic determinants of urinary tract infection susceptibility in the murine and human urinary tract infection model. (a) Infections of the urinary tract give rise to acute pyelonephritis, acute cystitis or asymptomatic bacteriuria. (b) Genetic control at the proximal level of the TLR4 signalling cascade (green) determines whether an innate immune response will be activated by infection. Gene deletions (\(Tlr4, MyD88, Trif, Tram\)) abrogate response, as well as symptoms and disease, thus protecting the infected host from acute disease and tissue damage. Genetic control at the distal level of the TLR4 signalling cascade (red) determines the efficiency of the antibacterial defense. Gene deletions (\(Irf3, Ifnb1\)) cause acute pyelonephritis and renal tissue damage. In addition, perturbations of neutrophil recruitment and function drastically increase the susceptibility to APN and renal scarring (\(mCxcr2\)). (c) Genes associated with UTI susceptibility in the murine UTI model. *IL-1 and inflammasome genes [48].
in Tlr4−/− and Myd88−/− mice and low in Trif mutant mice and there is no evidence of tissue disease in those mice [29,30].

Gene deletions that disturb the effector phase of the innate immune response increase the susceptibility to infection by decreasing the efficiency of bacterial clearance. In addition, an imbalance of transcriptional control may cause exaggerated inflammation, resulting in bladder or kidney disease. Gene deletions driving disease include both transcription factors and specific structural genes [1,2].

Transcription is differentially regulated by virulence factors and signalling pathways. P-fimbriated E. coli activates IRF-3 and IRF-7, which regulate type I IFN responses and associated antibacterial effector mechanisms. IRF-3 also works in concert with the AP-1 transcription factor, formed by c-Fos and c-Jun heterodimers, and triggers the acute phase response, neutrophil migration, adhesion and activation [11,17]. Irf3−/− mice are highly UTI-prone defined by acute and chronic morbidity. APN and uroepithelial cells are followed by massive renal abscess formation, 1 week after infection. Kidneys from Irf3−/− and Ifnb1−/− mice show an exaggerated, destructive neutrophil infiltrate. A similar phenotype occurs in Ifnβ−/− mice, illustrating the importance of IRF-3-dependent transcription, which regulates Ifnb1 expression and IFN-β dependent genes involved in bacterial clearance [11,31].

The importance of the neutrophil-dependent innate immune response is further highlighted in mCxcr2−/− mice. Mice lack CXCL8 [interleukin (IL)-8], but express several chemokine ligands for the murine receptor CXCR2, including CXCL2/3 [macrophage inflammatory protein 2 (MIP 2)], CXCL1 [keratinocyte chemoattractant (KC)] and CXCL5 [epithelial neutrophil activating peptide-78 (ENA-78)]. An mCxcr2 deletion inactivates neutrophil recruitment virtually completely, and neutrophil activation is reduced [32]. mCxcr2−/− mice develop severe APN with uroepithelial cells, and surviving mice remain chronically infected, with signs of kidney disease, resembling renal scarring in humans [32–35] (Fischer et al., in preparation). Long-term studies revealed no alleviation of the damage process by macrophages forming foam cells or specific immune cells, including T-lymphocytes and plasma cells [36].

Antibacterial peptides contribute to UTI resistance, but in contrast to humans, only one cathelicidin is expressed in the murine urinary tract [37]. Camp−/− mice, deficient for the cathelin-related antimicrobial peptide (CRAMP), show elevated bacterial numbers [38], increased sepsis-associated mortality and elevated kidney size compared with wild-type mice [37,39]. In mice, TLR11 is strongly expressed in the kidneys and influences renal infection in the murine UTI model. Kidneys from Tlr11−/− mice are massively infected compared with wild-type mice, with defective neutrophil infiltration [40]. Carbonic anhydrase 2 deficient mice have metabolic acidosis, impaired urine acidification and decreased renal bacterial clearance. Car2−/− mice had increased baseline neutrophil-gelatinase-associated lipocalin mRNA and protein but a decreased response to infection [41].

Additional genes have been suggested to affect UTI susceptibility especially in the urinary bladder, but their importance for acute cystitis pathogenesis remains unclear. Tamm–Horsfall protein (THP) or uromodulin acts as a receptor for type 1 fimbriae on the bladder mucosa [42,43], but Thp−/− mice showed higher bacterial numbers in the bladders [44] with no effect on kidney infection [44]. Thp mRNA expression was reduced in Cox2−/−, cyclooxygenase-2 deficient mice, which showed increased susceptibility to type 1 fimbriated E. coli [45]. TLR5 is expressed in the urinary tract mucosa and Tlr5−/− mice show a gradual increase in bacterial numbers in the bladder, with superficial bacterial micro-abscesses in parallel with submucosal oedema [46]. Recently, a mechanistic and genetic basis for acute cystitis susceptibility was proposed, involving the activation of IL-1β and downstream genes, dysregulation of the inflammatory and activation of cytotoxic enzymatic pathways [47].

## Genetics of Human Urinary Tract Infection Susceptibility

Clinical studies clearly distinguish genetic repertoires of patients prone to APN from those who preferentially develop ABU, consistent with the dichotomy of genetic control in the murine UTI model (Fig. 1 and Table 1) [48–55].

It may seem counterintuitively that low TLR4 expression reduces the risk for symptomatic infection, but TLR4 expression is lower in children with ABU than in age-matched controls or APN patients [48]. The TLR4 promoter is highly polymorphic and TLR4 promoter genotypes with reduced function are common in children with ABU [49]. In contrast, structural TLR4 gene polymorphisms are relatively rare [56] and their functional contribution to human disease susceptibility remains unclear. In association studies, Hawn et al. [50] suggested that TLR4 Asp299Gly protected from recurrent cystitis in adults, but this was not seen in children. They also associated TLR5 +1174C/T with cystitis risk and TLR1 +1805G/T with protection from pyelonephritis [50]. The TLR4 +896 G allele had a higher
prevalence in UTI patients and TLR4 expression in monocytes was significantly lower in chronic cystitis patients than in controls. In addition, patients carrying the TLR2 Arg753Gln allele had a higher risk of UTI with gram-positive pathogens [51].

Consistent with the APN phenotype in Irf3−/− mice, polymorphisms affecting transcription factor expression have also been associated with susceptibility in APN-prone patients. IRF3 promoter polymorphisms -925A/G and -776C/T are strongly associated with human APN susceptibility, occurring in about 70% of APN-prone patients [11]. This association was confirmed in two separate, APN-prone populations. The minor allele frequency was decreased in APN compared with primary ABU and paediatric controls [11]. APN-prone children have also reduced CXCR1 expression levels compared with paediatric controls and reduced CXCR1 expression was detected in family members of the APN-prone children [52]. Sequencing revealed two heterozygous polymorphisms and three unique mutations in 32% of the patients compared with 8% of controls, which were predicted to reduce CXCR1 expression. The frequency of disease-associated CXCR1 polymorphisms was 54%, when reflux was excluded.

In association studies, a CXCR1 polymorphism +2608G/C and CXCL8 (IL8) gene polymorphisms -251A/T and +2767A/G were not APN associated [53], but the −251 TT CXCL8 genotype was significantly more frequent in children with dimercaptosuccinic acid (DMSA) scan negative APN. CCL2 (MCP-1) and CCL5 regulated on activation, normal T cell expressed and secreted (RANTES) polymorphisms and their receptors, CCR2 and CCR5, have been investigated and the CCL5 −403 G allele was significantly associated with UTI risk [54]. Finally, SELE (E-selectin), ICAM1, PECAM1 and ITGAM (CD11b) polymorphisms were investigated. The ICAM1 exon 4 (G/A) polymorphism was less common in patients who developed renal scars than in controls, possibly as a result of reduced leucocyte infiltration and tissue damage [57]. The functional importance of those associations remains to be defined.

VEGFA and TGFBI polymorphisms predispose to progressive renal disease [55,58,59]. The VEGFA -460T/C polymorphism and TGFBI −800G/A and −509C/T polymorphisms are associated with UTI and vesicoureteral reflux (VUR) in children [59] and the VEGFA −460C allele increased basal promoter activity by 71% compared with the wild-type sequence [60]. The TGFBI +869 CC genotype was more common in patients with renal scarring [61]. In a meta-analysis, the ACE I/D and T allele of TGFBI −509C/T polymorphisms were associated with renal scarring, although with a high degree of variability [62].
The susceptibility to UTI is also influenced by the repertoire of host cell receptors for bacterial adhesins and by soluble, antiadhesive molecules [63]. Due to P blood group dependent variation in receptor expression [63–65], individuals of blood group P₁ have an approximately 17-fold increased risk for APN and have an increased carriage of P-fimbriated E. coli in their intestinal flora [63–65]. In contrast, individuals of blood group P lack the Gb₃ glucosyl-transferase and fail to express functional...
receptors for P fimbriae [9]. Epithelial receptor expression is also influenced by the ABO blood group and secretor state [4] and individuals expressing globo-A are preferentially infected by *E. coli* expressing the prsG adhesin, which uses group A as a receptor [66]. By predicting the mucosal receptor repertoire, the P blood group is therefore a risk marker in APN.

**BACTERIAL MODULATION OF INNATE IMMUNITY**

Bacteria manipulate the innate immune response in the human urinary tract. A secreted TIR domain homologue inhibits MyD88 and inflammasome activation [67]. ABU strains modulate host gene expression, by suppressing RNA polymerase II in patients with ABU [17**]. As a result of mutual adaptive strategies, bacteria adjust to individual hosts. During long-term ABU, *E. coli* 83972 reisolates showed host-specific reproducible genome alterations, suggesting that the evolution of fitness for the urinary tract is ‘personal’ [68].

**URINARY TRACT INFECTION SUSCEPTIBILITY AND FUTURE RISK**

Assessing UTI susceptibility and selecting appropriate therapeutic interventions is essential, in view of the high prevalence of UTIs and their significance to health and society. UTIs are common, encountered at all levels of healthcare whether primary or tertiary and consume considerable healthcare costs. It is estimated that 40–50% of women and 5% of men worldwide will develop UTI at least once in their lifetime, and UTIs account for more than 1 million hospitalizations and $1.6 billion in medical expenses annually, in the USA. UTIs also cause premature delivery and perinatal mortality, chronic renal disease and renal failure, unless properly treated. UTIs have an incidence of 5% in children less than 12 years old. Up to 30% of children with APN developed renal scars following UTI and this process is associated with long-term morbidity such as hypertension, complications of pregnancy and renal failure if scarring is extensive. Thus, the disease burden of UTI is significant, if not optimally managed.

Yet, the management of these patients remains unsatisfactory. Despite the urgent need, molecular tools are not used routinely to identify individuals at risk, resulting in a worldwide lack of consensus and uniform tools. Selection criteria for further radiological imaging and invasive fluoroscopy will thus remain unclear, guided only by best practices. The genes discussed above are biomarkers of UTI susceptibility or resistance. It is time to start including genetic markers in the daily risk assessment in UTI-prone patients to validate genes or gene combinations with optimal predictive power in the different UTI-prone patient groups.

**CONCLUSION**

UTI susceptibility is influenced by the genetic make up of the host, especially by genes that regulate the innate immune response to infection. Functionally relevant genes are regulatory rather than structural, suggesting that control of gene expression is essential. Thus, unlike the rare, monogenic disorders defined by gene loss, UTI susceptibility is defined by the efficiency of the host defense. Furthermore, emerging data suggest that different molecular response pathways and genes characterize patients with APN, acute cystitis or ABU. To further validate the power of genetic variants in UTI risk assessment, clinical study criteria should be coordinated between study centres.

**Acknowledgements**

Images from the murine UTI model in Fig. 2 were kindly provided by Dr Manoj Puthia, Department of Microbiology, Immunology and Glycobiology, Institute for Laboratory Medicine, Lund University, Lund, Sweden.

**Financial support and sponsorship**

We gratefully acknowledge the support of the Swedish Medical Research Council, Medical Faculty (Lund University), Swedish Cancer Society, Österlund and Sharon D. Lund Foundation, Anna-Lisa and Sven Erik Lundgren, Maggie Stephens, Inga-Britt and Arne Lundberg and HF Forssman Foundations, The Royal Physiographic Society and the Network of Excellence: EuroPathoGenomics.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES AND RECOMMENDED READING**

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Ragnarsson-Börjesson, L. N. Gronberg-Hernandez J, et al. Genetics of innate immunity and UTI susceptibility. Nat Rev Urol 2011; 8:449–468.
2. Zivkovic M, Stojkovic L, Spasojevic-Dimitrijeva B, et al. Genetic factors underlying susceptibility to acute pyelonephritis and postinfectious damage. In: Recent advances in the field of urinary tract infections, Nukes T; chapter 7, 2013.
3. Lundstedt AC, Lajonchu-Pud L, Ragnarsson-Börjesson B, et al. Inherited susceptibility to acute pyelonephritis: a family study of urinary tract infection. J Infect Dis 2007; 195:1227–1234.
4. Scholes D, Hawn TR, Roberts PL, et al. Family history and risk of recurrent cystitis and pyelonephritis in women. J Urol 2010; 184:564–569.
5. Scholes D, Hooton TM, Roberts PL, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis 2000; 182:1177–1182.
6. Svanborg C. Urinary tract infections in children: microbial virulence versus host susceptibility. Adv Exp Med Biol 2013; 764:205–210.
Urinary tract infection susceptibility: Godaly et al.

7. Ragnarsdottir B, Svanborg C. Susceptibility to acute pyelonephritis or asymptomatic bacteriuria: host-pathogen interaction in urinary tract infections. Pediatr Nephrol 2012; 27:207–209.

8. Nielubowicz GR, Mobile HL. Host-pathogen interactions in urinary tract infection. Nat Rev Urol 2010; 7:430–441.

9. Leffler H, Svanborg-Eden C. Chemical identification of a glycosphingolipid receptor for escherichia coli attaching to human urinary tract epithelial cells and agglutinating human erythrocytes. FEMS Microbiol Lett 1980; 8:127–134.

10. Hedlund M, Svensson M, Nilsson Å, et al. Role of the ceramide signaling pathway in cytokine responses to pribamitated escherichia col. J Exp Med 1996; 183:1–8.

11. Fischer H, Hutley N, Ragnarsdottir B, et al. Pathogen specific, tlr3-dependent signaling and innate resistance to human kidney infection. PLoS Path 2010; 6:e1001109.

12. Yamamoto M, Sato S, Hemmi H, et al. Essential role forifr in activation of the signaling cascade shared by tlr2 and tlr4. Nature 2002; 420:324–329.

13. Schwartz DJ, Kalas V, Pinkner JS, et al. Positively selected fimn resides enhance virulence during urinary tract infection by altering fimn conformation. Proc Natl Acad Sci U S A 2013; 110:15530–15537.

In this article, the authors propose that UPEC virulence is adjusted by the FimH conformation.

14. Lane MC, Atten CJ, Smith SN, Mobile HL. Expression of flagella is coincident with uropathogenic escherichia coli ascension to the upper urinary tract. Proc Natl Acad Sci U S A 2007; 104:16669–16674.

15. Miao Y, Abraham SN. Kidney alpha-intercalated cells and lipocan 2: defending the urinary tract. J Clin Invest 2014; 129:2844–2854.

In this commentary, the authors summarize recent knowledge of specialized kidney cells that are able to sense and promote clearance of infecting bacteria.

16. Ingersoll A, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol 2013; 6:1041–1053.

This review addresses special aspects of bladder biology that challenge current dogmas.

17. Hutley N, Ambite I, Hernandez JG, et al. Bacterial control of host gene expression through flagella. J Clin Invest 2013; 123:2366–2379.

In this article, the authors demonstrate that ABU strains adjust the host environment to their presence by suppressing RNA polymerase II dependent host gene expression.

18. Godaly G, Bergsten G, Hang L, et al. Neutrophil recruitment, chemokine receptors, and resistance to mucosal infection. J Leuk Biol 2001; 69:899–906.

19. Ambite I, Hutley N, Godaly G, Svanborg C. Urinary tract infections and the mucosal immune system. In: Mucosal Immunology, 4th edition. Mestecky J, ed. Mims Press, 2014; 129:2844–2854.

20. Nielsen KL, Dynesen P, Larsen P, Frimodt-Moller N. Role of urinary cathelicidin ll-37 and human beta-defensin 1 in uncomplicated escherichia coli urinary tract infections. Infect Immun 2014; 82:1572–1578.

In this clinical investigation, the authors demonstrate that the concentration of LL-37 in urine is associated with UTI susceptibility.

21. Morrison G, Klanswog F, Davidson D, Dorin J. Characterization of the mouse beta defensin 1, defb1, mutant mouse model. Infect Immun 2002; 70:3053–3060.

22. Shahin R, Engberg I, Hagberg L, Svanborg-Eden C. Neutrophil recruitment and bacterial clearance correlated with lps responsiveness in local gram-negative infection. J Immunol 1987; 138:3475–3480.

23. Hopkins W, Gondron-Fitzpatrick A, McCarthy DO, et al. Lipopolysaccharide-responder and nonresponder c3 mouse strains are equally susceptible to an induced escherichia coli urinary tract infection. Infect Immun 1999; 64:1366–1372.

24. Poitokas A, He X, Smirnova J, et al. Defective lps signaling in c3 h/hec and c3hec/hec mice that affect the susceptibility to gram-negative infections. J Immunol 1985; 134:418–412.

25. Samuelsson P, Hang L, Wulfh B, et al. Toll-like receptor 4 expression and cytokine responses in the human urinary tract mucosa. Infect Immun 2004; 72:3179–3186.

26. Hagberg L, Brels D, Svanborg-Eden C. Evidence for separate genetic defects in c3 h/hec and c3hec/hec mice that affect the susceptibility to urinary tract infections. J Exp Med 2004; 199:917–926.

27. Svanborg C, Innate immunity and genetics of UTI susceptibility urinary tract infection; molecular advances and novel therapies. In: Molecular UTI Conference: Urinary Tract Infection: Molecular Advances and Novel Therapies, 25-27 August 2014; Malmo, Sweden.

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

www.co-infectiousdiseases.com
Urinary tract infections

60. Stevens A, Soden J, Brenchley PE, et al. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 2003; 63:812–816.

61. Yim HE, Bae IS, Yoo KH, et al. Genetic control of vegf and tgf-beta1 gene polymorphisms in childhood urinary tract infection and vesicoureteral reflux. Pediatr Res 2007; 62:189–187.

62. Zaffanello M, Tardivo S, Cataldi L, et al. Genetic susceptibility to renal scar formation after urinary tract infection: a systematic review and meta-analysis of candidate gene polymorphisms. Pediatr Nephrol 2011; 26:1017–1029.

63. Lomberg H, Hanson L, Jacobsson B, et al. Correlation of P blood group phenotype, vesicoureteral reflux and bacterial attachment in patients with recurrent pyelonephritis. N Engl J Med 1983; 308:1189–1192.

64. Lomberg H, Jodal U, Svanborg-Edén C, et al. P1 blood group and urinary tract infection. Lancet 1981; i:551–552.

65. Stapleton A, Nudelman E, Clausen H, et al. Binding of uropathogenic Escherichia coli r45 to glycolipids extracted from vaginal epithelial cells is dependent on histo-blood group secretor status. J Clin Invest 1992; 90:965–972.

66. Lindstedt R, Larson G, Falk P, et al. The receptor repertoire defines the host range for attaching escherichia coli strains that recognize globo-a. Infect Immun 1991; 59:1086–1092.

67. Ciril C, Wieser A, Yadav M, et al. Subversion of toll-like receptor signaling by a unique family of bacterial toll/interleukin-1 receptor domain-containing proteins. Nat Med 2008; 14:399–406.

68. Zdziaski J, Bruszczewicz E, Wult B, et al. Host imprints on bacterial genomes – rapid, divergent evolution in individual patients. PLoS Path 2010; 6:e1001078.